



PPD® LABORATORIES
BIOANALYTICAL LAB



Biosimilars Capabilities and Expertise Overview

PPD Laboratories bioanalytical lab provides **comprehensive services and capabilities** for the **development of biosimilar drugs**. Our biologics team has **extensive** experience, **broad** technical capabilities and a **deep understanding** of the regulatory pathway needed to keep clients' projects on track.

Extensive and relevant biosimilars experience

PPD Laboratories bioanalytical lab has developed assays and tested more than 300,000 samples for the following biosimilars:

- Rituximab
- Filgrastim and Pegfilgrastim
- Trastuzumab
- Bevacizumab
- Etanercept
- Epoetin
- Palivizumab for RSV
- Low molecular weight heparin
- Infliximab
- Adalimumab

Multiple assays formats

- ELISA (chromogenic, chemiluminescent and fluorescent)
- MSD electrochemiluminescence
- GYROS
- Radioimmunoassay (RIA)
- Radioimmunoprecipitation (RIP)

Unique development needs for biosimilars

- They must demonstrate comparable results (safety, purity, potency, stability and immunogenicity) to the innovator product and across product lots
- Assays developed for the innovator product may require adjustments and/or redevelopment and validation due to the physicochemical attributes and functional activity of the biosimilar
- Biologics by nature are more variable than small molecules, making the analytical methods subject to variation across instruments, critical reagents, operators and even day-to-day and lab-to-lab differences
- Biosimilars development is complex and each project has specific needs

Broad biologics capabilities and experience

Our biologics development team has experience with a range of sample preparation approaches from simple protein denaturation and digestion to complex affinity capture enrichment techniques.

Capabilities include:

- Pharmacokinetic (PK) assays
- Anti-drug antibodies (ADA) studies
- Neutralizing antibody (NAb) assays

PPD Laboratories bioanalytical lab has experience with eight of the top 10 best-selling biosimilars of 2018¹

1. Data on file from 2018 IRC report

Important regulatory exposure

PPD Laboratories bioanalytical lab was founded in 1985 and since then, has hosted an average of two to three on-site Food and Drug Administration (FDA) inspections every year. In the past five years we have supported more than 17 biosimilar programs for FDA and European Medicines Agency (EMA) submissions. This consistent and extensive regulatory interface ensures our procedures reflect current expectations and our data quality remains high.

PPD Laboratories is one of the few labs that has been audited for its work in support of multiple biosimilar submissions. These audits encompassed PK, ADA and cell-based assays. Our comprehensive biosimilar development experience and excellent regulatory history mean you can be confident your development program will stay on track.



17+ biosimilar programs destined for regulatory submission

High throughput capabilities

- Validated automated liquid-handling systems for ligand-binding assays
- Electronic notebook systems for data review
- Sustainable throughput of >10,000 PK samples per month demonstrated across multiple studies

In addition to working on eight of the best-selling biomiliars of 2018, our experience spans the therapeutic spectrum and includes oncology, auto-immune diseases, metabolic disorders and vaccines.
